CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Dual Growth Factordrug
Likely dose
Dual Growth Factor 10,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00362414
NCT00362414Phase 2Completed
CompareCT.gov

Safety of Beta-hCG + Erythropoietin in Acute Stroke

University of California, Irvine·interventional·Posted Aug 10, 2006·Updated Aug 29, 2016

In Brief

A Phase 2 clinical trial evaluating Dual Growth Factor for Acute Stroke. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Stroke
CountriesUnited States
CollaboratorsStem Cell Therapeutics Corp., Hoag Memorial Hospital Presbyterian

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 10, 2006
Enrollment StartAug 1, 2006
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.9 years ago

Interventions

Dual Growth Factordrug

10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation 30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation